Start-Up Eidos Surfs Crest Of TTR Amyloidosis Wave
Emerging Company Profile: The Phase III success of Pfizer's tafamidis means Eidos’ protein misfolding drug AG10 is not the first – but it is validated and differentiated, says BridgeBio-backed start-up Eidos.
You may also be interested in...
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
Is Eidos a goose that could lay a golden egg? BridgeBio wants to own it all, instead of two-thirds, in case its subsidiary's lead program in TTR amyloidosis succeeds in Phase III.
The company emerged in 2017 with $135m to spin out rare genetic disease-focused subsidiaries. Now with 18 start-ups and two near-term filings for drug approvals, BridgeBio will fund existing programs as they progress and continue to buy new assets.